A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk.

CONCLUSIONS: The DS was prognostic for risk and predicted RT benefit for DCIS patients. DS identified a clinically meaningful low risk group, and a group with elevated 10-year risks that received substantial RT benefit over baseline. PMID: 30054280 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30054280?dopt=Abstract

Source: Clinical Cancer Research - July 27, 2018 Category: Cancer & Oncology Authors: Bremer T, Whitworth P, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirstrom K, Zhou W, Amini RM, Wärnberg F Tags: Clin Cancer Res Source Type: research